SAM
Sectoral Asset Management Portfolio holdings
AUM
$151M
This Quarter Return
+3.76%
1 Year Return
+14.02%
3 Year Return
+79.35%
5 Year Return
+153.48%
10 Year Return
+511.68%
AUM
$151M
AUM Growth
+$151M
(+18%)
Cap. Flow
+$26.9M
Cap. Flow
% of AUM
17.79%
Top 10 Holdings %
Top 10 Hldgs %
42.26%
Holding
109
New
25
Increased
23
Reduced
25
Closed
15
Top Buys
| 1 |
MBX
MBX Biosciences, Inc. Common Stock
MBX
|
$2.19M |
| 2 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$2.16M |
| 3 |
Replimune Group
REPL
|
$2.15M |
| 4 |
Oric Pharmaceuticals
ORIC
|
$2.15M |
| 5 |
Solid Biosciences
SLDB
|
$2.05M |
Top Sells
| 1 |
Medtronic
MDT
|
$2.14M |
| 2 |
Gilead Sciences
GILD
|
$1.37M |
| 3 |
Tenet Healthcare
THC
|
$1.21M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
$1.12M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$994K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
ArriVent BioPharma
AVBP
$776M
| $775K | 0.51% |
35,580
+25,490
| +253% | +$555K |
|
52
uniQure
QURE
$896M
| $773K | 0.51% |
55,450
-2,100
| -4% | -$29.3K |
|
53
Tarsus Pharmaceuticals
TARS
$2.47B
| $751K | 0.5% |
18,535
+1,285
| +7% | +$52.1K |
|
54
Trevi Therapeutics
TRVI
$883M
| $734K | 0.48% |
134,150
+52,350
| +64% | +$286K |
|
55
MoonLake Immunotherapeutics
MLTX
$3.54B
| $713K | 0.47% |
15,108
| – | – |
|
56
RadNet
RDNT
$5.52B
| $711K | 0.47% |
12,500
-7,500
| -38% | -$427K |
|
57
Legend Biotech
LEGN
$6.41B
| $697K | 0.46% |
19,627
-16,338
| -45% | -$580K |
|
58
BridgeBio Pharma
BBIO
$9.89B
| $695K | 0.46% |
16,085
| – | – |
|
|
BOLD
59
Boundless Bio
BOLD
$25.1M
| $685K | 0.45% |
678,574
| – | – |
|
60
Amicus Therapeutics
FOLD
$2.34B
| $685K | 0.45% |
119,585
+12,000
| +11% | +$68.8K |
|
61
Centene
CNC
$14.3B
| $679K | 0.45% |
+12,500
| New | +$679K |
|
|
OMDA
62
Omada Health, Inc. Common Stock
OMDA
$1.36B
| $631K | 0.42% |
+34,500
| New | +$631K |
|
63
Ascendis Pharma
ASND
$11.8B
| $599K | 0.4% |
3,471
+1,380
| +66% | +$238K |
|
64
Cigna
CI
$80.3B
| $595K | 0.39% |
+1,800
| New | +$595K |
|
65
Syndax Pharmaceuticals
SNDX
$1.41B
| $593K | 0.39% |
+63,300
| New | +$593K |
|
|
KMTS
66
Kestra Medical Technologies, Ltd. Common Stock
KMTS
$829M
| $580K | 0.38% |
+35,000
| New | +$580K |
|
67
Roivant Sciences
ROIV
$8.15B
| $564K | 0.37% |
50,007
+1,100
| +2% | +$12.4K |
|
68
Zai Lab
ZLAB
$3.68B
| $554K | 0.37% |
15,840
-14,080
| -47% | -$492K |
|
69
Bristol-Myers Squibb
BMY
$96B
| $500K | 0.33% |
10,800
-8,700
| -45% | -$403K |
|
|
HNGE
70
Hinge Health, Inc.
HNGE
$4.4B
| $476K | 0.31% |
+9,206
| New | +$476K |
|
71
CVRx
CVRX
$205M
| $432K | 0.29% |
73,500
+5,000
| +7% | +$29.4K |
|
72
PTC Therapeutics
PTCT
$3.92B
| $417K | 0.28% |
8,535
+185
| +2% | +$9.04K |
|
73
Incyte
INCY
$16.5B
| $413K | 0.27% |
6,060
-85
| -1% | -$5.79K |
|
74
Cytokinetics
CYTK
$4.23B
| $387K | 0.26% |
11,723
-6,345
| -35% | -$210K |
|
75
Neurocrine Biosciences
NBIX
$13.8B
| $372K | 0.25% |
2,960
+55
| +2% | +$6.91K |
|